Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Although new targets and therapies are on the horizon, current myositis treatment strategies rely ...
Please provide your email address to receive an email when new articles are posted on . WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over ...
Verywell Health on MSN
Juvenile Myositis Symptoms and Outlook
Medically reviewed by Dale Garber, MD Key Takeaways Juvenile myositis causes muscle inflammation and weakness, with skin ...
TipRanks on MSN
Pfizer’s Phase 3 Study on PF-06823859: A Potential Game-Changer for Myositis Treatment
Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 clinical study titled A PHASE 3, ...
H.C. Wainwright analyst Douglas Tsao reiterates a Buy rating on Argenx (ARGX) with a $617 price target after the company said it is advancing efgartigimod subcutaneous in all three subtypes of ...
PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell ...
Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable ...
PHILADELPHIA, May 16, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies ...
NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback